[1]Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines[J]. Nat Rev Microbiol, 2012, 10: 681-692. [2]Matsukura T, Sugase M. Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger[J]. Int J Gynecol Cancer, 2008, 18: 1042-1050. [3]de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis[J]. Lancet Infect Dis, 2007, 7: 453-459. [4]Maine D, Hurlburt S, Greeson D. Cervical cancer prevention in the 21st century: cost is not the only issue[J]. Am J Public Health,2011,101: 1549-1555. [5]Haque A, Kouriba B, Aissatou N, et al.Eliminating cervical cancer in Mali and Senegal, two sub-saharan countries: insights and optimizing solutions[J].Vaccines (Basel), 2020, 8:181-192. [6]Wang R, Guo XL, Wisman GB, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China[J]. BMC Infect Dis, 2015, 15: 257-267. [7]Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide[J]. J Pathol, 1999, 189: 12-19. [8]赵群,陈志恒,朱小玲,等. 湖南省24817例体检妇女筛查宫颈病变结果分析[J]. 基础医学与临床, 2015, 35: 435-438. [9]秦晓林,闫恺,段桂开,等.深圳地区36155例女性HPV感染现状与分型研究[J].检验医学与临床,2019,16:1037-1039. [10]Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer[J]. Int J Cancer, 2012, 131: 2349-2359. [11]Carozzi FM, Ocello C, Burroni E, et al. Effectiveness of HPV vaccination in women reaching screening age in Italy[J]. J Clin Virol, 2016, 84: 74-81. [12]Alder S, Perinetti C, Mints M, et al. Acceptance of human papilloma virus (HPV)vaccination among young women in a country with a high prevalence of HPV infection[J]. Int J Oncol, 2013, 43: 1308-1310. |